Medicine by the Numbers
A Collaboration of TheNNT.com and AFP
Nebulized Hypertonic Saline for Bronchiolitis
Am Fam Physician. 2018 Jul 1;98(1):23-24.
Details for This Review
Study Population: Children younger than 24 months with bronchiolitis (3,209 participants in 24 trials). Most trials excluded patients who required mechanical ventilation, intensive care, or those who had oxygen saturation less than 85% on room air.
Efficacy End Points: Length of hospital stay, rate of hospitalization
Harm End Points: Tachycardia, hypertension, pallor, tremor, nausea, vomiting, diarrhea, and acute urinary retention
Narrative: Bronchiolitis is the most common lower respiratory tract infection in infants, with respiratory syncytial virus being the leading cause. Airway edema and mucus plugging are believed to be the pathologic processes causing morbidity in cases of viral bronchiolitis. Supportive treatment is the standard of care. In addition, nebulized hypertonic saline may be beneficial in relieving symptoms.
A systematic review included double-blind, randomized, controlled clinical trials evaluating the effect of nebulized hypertonic (3% or higher) saline solution alone or in conjunction with bronchodilators in infants with acute bronchiolitis compared with nebulized normal (0.9%) saline.1 Nebulized hypertonic saline resulted in a statistically significant reduction in length of hospital stay (mean difference: −0.45 day; 95% confidence interval [CI], −0.82 to −0.08). Nebulized hypertonic saline also reduced the risk of hospitalization by 20% compared with 0.9% saline (relative risk [RR] = 0.80; 95% CI, 0.67 to 0.96). No significant adverse events related to hypertonic saline inhalation were reported.
The lead author of this systematic review published a Cochrane review on the same topic in 2013.2 That meta-analysis showed a mean reduction of 1.2 days (95% CI, 0.8 to 1.5 days) in the length of hospital stay and no significant difference in the rate of hospitalization.2 We chose to write our summary based on the 2015 meta-analysis because it is more recent and includes several recent trials and approximately 2,000 more patients than the 2013 Cochrane review.
A 2014 meta-analysis reported an approximately one-day decrease in the length of hospital stay (weighted mean difference = −0.96; 95% CI, −1.38 to −0.54) in patients who received nebulized hypertonic saline compared with normal saline.3 This meta-analysis also showed a significant decrease in hospital admission rate (RR = 0.59; 95% CI, 0.37 to 0.93) after receiving nebulized hypertonic saline.
A 2017 randomized controlled trial enrolling 777 patients with bronchiolitis failed to show any significant difference in rate of hospital admission or length of hospital stay between the groups (nebulized hypertonic saline and nebulized normal saline).4
No significant adverse events related to hypertonic saline inhalation were observed in the trials reported in systematic reviews. No patients withdrew because of adverse events or clinical deterioration.
Caveats: The results of three large meta-analyses of randomized double-blind clinical trials suggest a high quality of evidence and show some benefits in using nebulized hypertonic saline compared with normal saline in children with bronchiolitis.1–3 However, the most concerning issue arising from reviewing the data is that most of the trials published after 2013, including two large multicenter European trails, have reported negative results.4–8 Heterogeneity among the trials and existence of effect modifiers could be responsible for this inconsistency.
The authors of the 2015 review offer an explanation for this discrepancy among the trials.1 A subgroup analysis performed by these authors found that trials in which virologic testing was available showed a significantly greater effect size of nebulized hypertonic saline (measured by reduction of length of hospital stay and rate of hospitalization) than trials without such testing. Thus, the diagnostic accuracy of bronchiolitis may affect the treatment outcomes.
The only consistent finding among all trials is the absence of any serious adverse event associated with the use of hypertonic saline. Considering the prevalence of bronchiolitis and the financial and emotional cost of hospitalization, possible reduction in admission rate and hospital stay with minimal adverse events provides enough evidence to recommend this treatment for acute bronchiolitis.
Most trials excluded patients who required mechanical ventilation or intensive care, and those who had oxygen saturation less than 85% on room air. Therefore, the findings of this review might not apply to infants with more severe bronchiolitis.
Despite reported benefits associated with the use of hypertonic saline for bronchiolitis, we have chosen a yellow recommendation because the more recent trials and systematic reviews have shown either much smaller effect size or no benefit at all compared with the older trials.
Copyright 2018 The NNT Group (theNNT.com). Used with permission.
This series is coordinated by Dean A. Seehusen, MD, MPH, AFP Assistant Medical Editor, and Daniel Runde, MD, from the NNT Group.
A collection of Medicine by the Numbers published in AFP is available at https://www.aafp.org/afp/mbtn.
This review is available from the NNT Group at http://www.thennt.com/nnt/nebulized-hypertonic-saline-bronchiolitis/.
Referencesshow all references
1. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized hypertonic saline for acute bronchiolitis: a systematic review [published correction appears in Pediatrics. 2016;137(4):pii:e20160017]. Pediatrics. 2015;136(4):687–701....
2. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;(7):CD006458.
3. Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: an updated meta-analysis. Pediatr Neonatol. 2014;55(6):431–438.
4. Angoulvant F, Bellêttre X, Milcent K, et al.; Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) Study Group. Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2017;171(8):e171333.
5. Sharma BS, Gupta MK, Rafik SP. Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial. Indian Pediatr. 2013;50(8):743–747.
6. Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr. 2014;168(7):664–670.
7. Teunissen J, Hochs AH, Vaessen-Verberne A, et al. The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial. Eur Respir J. 2014;44(4):913–921.
8. Everard ML, Hind D, Ugonna K, et al.; SABRE Study Team. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014;69(12):1105–1112.
Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Access the latest issue of American Family Physician